source
- Ultragenyx’s Angelman therapy fails Phase 3, stock drops over 43% and company announces strategic reviewUltragenyx reported that its investigational Angelman syndrome drug apazunersen did not meet the primary cognitive endpoints in a Phase 3 trial. The lack of efficacy means the therapy will not prov…
- Akeso and Summit report ivonescimab meets overall survival endpoint in Phase 3 lung cancer trialAkeso and its partner Summit said the Phase 3 trial of ivonescimab, a PD-1xVEGF bispecific antibody, has met its overall survival endpoint in a selected group of lung cancer patients. The announcem…Endpoints · 2mo agoPositive readoutPositive